Finlay, A. Y., Barker, J. N., Burden, A. D., Griffiths, C. E. M., Kirby, B., Goodman, M. L., Neill, C. and Warren, R. B. (2022) Secukinumab improves the quality‐of‐life of family members and partners of people with psoriasis: Family Dermatology Life Quality Index (FDLQI) results from a randomised open‐label study (SIGNATURE). JEADV Clinical Practice, 1(3), pp. 207-218. (doi: 10.1002/jvc2.42)
Text
274143.pdf - Published Version Available under License Creative Commons Attribution. 744kB |
Abstract
Background: The Family Dermatology Life Quality Index (FDLQI) was developed to meet a need for a dermatology‐specific family member/partner quality‐of‐life (QoL) measure. This paper focuses on the analysis and interpretation of FDLQI data (used as an exploratory outcome) collected in the SIGNATURE study. Objectives: To measure the impact of secukinumab therapy for moderate to severe plaque psoriasis on the QoL of family members/partners of patients. Methods: Randomised, open‐label, non‐comparator study in 53 dermatology centres in the UK and Republic of Ireland. Patients received secukinumab 300 or 150 mg subcutaneously weekly for 4 weeks, then 4‐weekly. FDLQI Results: Family members of PASI 75 responders and non‐responders showed improved FDLQI compared to baseline, greater for responders. There was a high level of correlation between FDLQI and Dermatology Life Quality Index (DLQI) scores and positive correlations across all mapped FDLQI and DLQI questions, and a close association between the scales at all timepoints. The estimated FDLQI scores were consistently 56% of those obtained for DLQI. There was an improvement for all FDLQI questions at Week 16 with a mean total score change of 8.2. Most family member subjects had an improved score for all FDLQI questions (75%–91%, Week 12, and 77%–91%, Week 16). Family subjects with a corresponding patient visit DLQI score >10 improved for all FDLQI questions at Week 16 (mean total score change of 5.2). Conclusions: Successful therapy for severe psoriasis greatly improved QoL of family members/partners. The FDLQI questionnaire responds well and appropriately to major changes in the disease severity of those affected by plaque psoriasis.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Burden, Professor David |
Authors: | Finlay, A. Y., Barker, J. N., Burden, A. D., Griffiths, C. E. M., Kirby, B., Goodman, M. L., Neill, C., and Warren, R. B. |
College/School: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity |
Journal Name: | JEADV Clinical Practice |
Publisher: | Wiley |
ISSN: | 2768-6566 |
ISSN (Online): | 2768-6566 |
Published Online: | 29 June 2022 |
Copyright Holders: | Copyright © 2022 The Authors |
First Published: | First published in JEADV Clinical Practice 1(3): 207-218 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record